Sanofi (France)

2068 articles about Sanofi (France)

• 

  Biogen, Novartis, Sanofi Cull Candidates in Q1 Pipeline Reprioritizations

  5/5/2023

  The companies said in first-quarter earnings calls that they want to restructure R&D, cut costs and shift away from high-risk drug development to focus areas.
• 

  Sanofi Deepens Pompe Disease Focus with $150M Maze Partnership

  5/2/2023

  For $150 million upfront, Sanofi will gain access to Maze’s lead asset MZE001, which inhibits the GYS1 protein in the rare genetic disorder.

• Maze Therapeutics Announces Exclusive Worldwide License Agreement with Sanofi for MZE001, an Oral Substrate Reduction Therapy for the Treatment of Pompe Disease

  5/1/2023

  Maze Therapeutics announced the signing of an exclusive worldwide license agreement with Sanofi for Maze’s glycogen synthase 1 program, including clinical candidate MZE001, which is currently in development for the treatment of Pompe disease and other potential indications.

• Press Release: Strong Q1 growth driven by Specialty Care, Vaccines and CHC

  4/27/2023

  We have started 2023 with strong results, delivering double-digit sales growth across our Specialty Care, Vaccines and Consumer Healthcare businesses.

• Press Release: Sanofi completes acquisition of Provention Bio, Inc.

  4/27/2023

  Sanofi announced the completion of its acquisition of Provention Bio, Inc. The acquisition adds TZIELD, an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi’s core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile.

• Press Release: Hart-Scott-Rodino waiting period expires for Sanofi’s acquisition of Provention Bio, Inc.

  4/26/2023

  Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.

• Press Release: Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements

  4/11/2023

  Sanofi has simplified its contractual arrangements relating to the development and commercialization of Beyfortus in the United States.

• Press Release: Sanofi announces withdrawal and refiling of Premerger Notification and Report Form under the HSR Act and extension of tender offer to acquire Provention Bio, Inc.

  4/10/2023

  Sanofi announced that it has withdrawn and refiled its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with Sanofi’s pending acquisition of Provention Bio, Inc.

• Sanofi Breaks Ground on State-of-the-Art Facility in Swiftwater for Sustainable Production of Pandemic Flu Vaccines

  4/4/2023

  Sanofi and the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, celebrated the groundbreaking of a new, state-of-the-art formulation and filling facility at Sanofi's Swiftwater site in Pennsylvania.

• Press Release: Two fitusiran Phase 3 studies published in The Lancet and The Lancet Haematology highlight potential to address unmet needs across all types of hemophilia

  4/4/2023

  Two studies, published in The Lancet and The Lancet Haematology, evaluating the efficacy and safety of fitusiran, an investigational siRNA therapy for the prophylactic treatment of adults and adolescents with hemophilia A or B, reinforce the potential of this investigational therapy to transform the current standard of care and address unmet needs for all types of hemophilia, regardless of inhibitor status.

• Press Release: Availability of the Q1 2023 Memorandum for modelling purposes

  3/30/2023

  Sanofi announced that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website.

• Press Release: Dupixent® demonstrates potential to become first biologic to treat COPD by showing significant reduction in exacerbations in pivotal trial 

  3/23/2023

  The primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

• Dupixent® (dupilumab) Demonstrates Potential to Become First Biologic to Treat COPD by Showing Significant Reduction in Exacerbations in Pivotal Trial

  3/23/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced the primary and all key secondary endpoints were met in a Phase 3 trial evaluating the investigational use of Dupixent® compared to placebo in adults currently on maximal standard-of-care inhaled therapy with uncontrolled chronic obstructive pulmonary disease and evidence of type 2 inflammation.

• Press Release: Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis 

  3/21/2023

  The European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

• Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis

  3/21/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the European Commission has approved Dupixent® in the European Union to treat severe atopic dermatitis in children aged 6 months to 5 years old who are candidates for systemic therapy.

• Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis

  3/18/2023

  Positive results from the clinical trial assessing Dupixent® in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis were presented.

• Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

  3/18/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi presented positive results from the clinical trial assessing Dupixent® in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermatitis.

• Press Release: Sanofi cuts U.S. list price of Lantus®, its most-prescribed insulin, by 78% and caps out-of-pocket Lantus costs at $35 for all patients with commercial insurance

  3/16/2023

  Sanofi announces that it will cut the list price of Lantus 100 Units/mL, its most widely prescribed insulin in the U.S., by 78 percent.

• 

  Sanofi Bolsters Diabetes Position with $2.9B Provention Buyout

  3/13/2023

  Sanofi will acquire diabetes leader Provention Bio for $25 per share for a total of $2.9 billion, the companies announced Monday. 

• Dupixent® (dupilumab) Application for Treatment of Chronic Spontaneous Urticaria (CSU) in Adults and Adolescents Aged 12 Years and Older Accepted for FDA Review

  3/7/2023

  Regeneron Pharmaceuticals, Inc. and Sanofi announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for Dupixent® to treat adults and adolescents aged 12 years and older with chronic spontaneous urticaria that is not adequately controlled with the current standard of care, H1 antihistamine treatment.